Pathological and microbiological impact of a gentamicin-loaded biocomposite following limited or extensive debridement in a porcine model of osteomyelitis.
Animal model
Antimicrobial carrier
Calcium sulphate
Hydroxyapatite
Osteomyelitis
Journal
Bone & joint research
ISSN: 2046-3758
Titre abrégé: Bone Joint Res
Pays: England
ID NLM: 101586057
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
entrez:
15
8
2020
pubmed:
15
8
2020
medline:
15
8
2020
Statut:
epublish
Résumé
CERAMENT|G is an absorbable gentamicin-loaded biocomposite used as an on-site vehicle of antimicrobials for the treatment of chronic osteomyelitis. The purpose of the present study was to investigate the sole effect of CERAMENT|G, i.e. without additional systemic antimicrobial therapy, in relation to a limited or extensive debridement of osteomyelitis lesions in a porcine model. Osteomyelitis was induced in nine pigs by inoculation of 10 All animals presented confirmatory signs of bone infection post-mortem. The estimated amount of inflammation was substantially greater in Groups A and B compared to Group C. In both Groups B and C, peptide nucleic acid fluorescence in situ hybridization (PNA FISH) of CERAMENT|G and surrounding bone tissue revealed bacteria embedded in an opaque matrix, i.e. within biofilm. In addition, in Group C, the maximal measured post-mortem gentamicin concentrations in CERAMENT|G and surrounding bone tissue samples were 16.6 μg/ml and 6.2 μg/ml, respectively. The present study demonstrates that CERAMENT|G cannot be used as a standalone alternative to extensive debridement or be used without the addition of systemic antimicrobials.Cite this article:
Identifiants
pubmed: 32793334
doi: 10.1302/2046-3758.97.BJR-2020-0007.R1
pii: BJR-9-394
pmc: PMC7393185
doi:
Types de publication
Journal Article
Langues
eng
Pagination
394-401Informations de copyright
© 2020 Author(s) et al.
Références
Bone Joint Res. 2018 Aug 4;7(7):447-456
pubmed: 30123494
Clin Microbiol Infect. 2015 May;21 Suppl 1:S1-25
pubmed: 25596784
J Bone Jt Infect. 2019 Mar 16;4(2):76-84
pubmed: 31011512
Antimicrob Agents Chemother. 2019 Jan 29;63(2):
pubmed: 30455228
Genome Announc. 2015 Oct 22;3(5):
pubmed: 26494663
Bone Joint J. 2016 Sep;98-B(9):1289-96
pubmed: 27587534
J Orthop Res. 2020 Aug;38(8):1793-1799
pubmed: 31943345
Bone Joint Res. 2016 Sep;5(9):427-35
pubmed: 27678329
J Bone Jt Infect. 2017 Jan 1;2(1):38-51
pubmed: 28529863
J Intern Med. 2014 Aug;276(2):111-9
pubmed: 24605880
FEMS Immunol Med Microbiol. 2008 Jan;52(1):13-22
pubmed: 18081847
Physiol Rep. 2014 Jul 22;2(7):
pubmed: 25052492
J Orthop Trauma. 2020 Jan;34(1):18-29
pubmed: 31464858
APMIS Suppl. 2013 May;(136):1-51
pubmed: 23635385
J Orthop Res. 2017 Oct;35(10):2211-2221
pubmed: 27958656
APMIS. 2011 Feb;119(2):111-8
pubmed: 21208278
Int J Artif Organs. 2011 Sep;34(9):781-8
pubmed: 22094557
PLoS One. 2019 Mar 14;14(3):e0213590
pubmed: 30870491
J Bone Jt Infect. 2016 Oct 1;1:59-64
pubmed: 28529855
Adv Wound Care (New Rochelle). 2018 Apr 1;7(4):105-113
pubmed: 29675336
Histopathology. 2009 Jun;54(7):847-53
pubmed: 19635104
Clin Microbiol Infect. 2012 Apr;18(4):395-400
pubmed: 22429460
Antimicrob Agents Chemother. 2016 Jun 20;60(7):3897-905
pubmed: 27067337
J Bone Jt Infect. 2018 Feb 20;3(1):27-36
pubmed: 29545993
J Bone Joint Surg Am. 2008 Aug;90(8):1751-8
pubmed: 18676908